Axitinib is under clinical development by Pfizer and currently in Phase II for Paraganglioma (Glomus Jugulare Tumor). According to GlobalData, Phase II drugs for Paraganglioma (Glomus Jugulare Tumor) have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Axitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Axitinib (Inlyta) is an anti-cancer agent. It is formulated as film-coated tablets and tablets for oral route of administration. It is indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy.Inlyta in combination with avelumab and pembrolizumab is indicated for the first-line treatment of patients with advanced or metastatic renal cell carcinoma (RCC).
The drug candidate is under development for the treatment of advanced melanoma, solid tumors including salivary gland cancers (SGCs) of the upper aerodigestive tract, paraganglioma, angiosarcoma, soft tissue sarcoma, chondrosarcoma, osteosarcoma, Ewing sarcoma, leiomyosarcoma, peripheral nerve sheath tumor (neurofibrosarcoma), rhabdomyosarcoma, synovial sarcoma, pleomorphic liposarcoma, neuroendocrine tumours of non pancreatic origin, recurrent glioblastoma, spindle cell squamous cell carcinoma , salivary gland cancer, gastrointestinal stromal tumor (GIST), clear cell squamous cell carcinoma , chordoma, non-small cell lung cancer, prostate cancer and ductal adenocarcinoma. It was also under development for the treatment of Kaposi sarcoma, metastatic melanoma, metastatic uveal melanoma, adrenocortical carcinoma, glioblastoma multiforme, thyroid cancer, metastatic breast cancer, metastatic colorectal cancer, gastric cancer, myelodysplastic syndrome, acute myelocytic leukemia, renal cell carcinoma, head and neck squamous cell carcinoma, metastatic pancreatic cancer, and metastatic hepatocellular carcinoma.
It was under development for the treatment of metastatic transitional (urothelial) tract cancer, bladder cancer, urethral cancer and ureter cancer.
Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of Axitinib’s drug-specific PTSR and LoA scores, buy the report here.